Synageva BioPharma is a publicly traded biopharmaceutical company with headquarters, research and development facilities in Lexington, MA, and research and production facilities in Athens, GA. Synageva was formed to concentrate on novel orphan treatments for rare diseases. Our lead program, SBC-102, an enzyme replacement therapy for LAL Deficiency, is in clinical development and has been granted orphan designation by the FDA. LAL Deficiency is a rare, serious and devastating disease that leads to significant morbidity and mortality. Synageva has additional orphan products in development. To ensure that these therapeutic candidates reach patients in need, Synageva has recruited a team with a proven record of discovery, development and commercial experience within rare diseases.
Our work is based on creating value for patients and their healthcare providers, our shareholders and our employees. Our success brings new treatments to patients and providers. We are building a sustainable business and value for our shareholders because good medicine is good business. Our culture attracts and retains principle-minded individuals of integrity, drive, energy and passion. – less